CISH and neoplasm: These autologous tumor-infiltrating lymphocytes with enhanced anti-tumor efficiency are generated by knocking out the gene cytokine-inducible SH2-containing protein (CISH) via CRISPR/Cas9 in patient-derived tumor-infiltrating lymphocytes once they are collected from tumors.